Compare Eli Lilly And Co (LLY) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs TotalEnergies SE — how do they compare? Eli Lilly And Co trades at $1,140.22 (market cap $1.02T), while TotalEnergies SE trades at $82.51 (market cap $179.99B). The key difference: Eli Lilly And Co is far larger — about 5.7× TotalEnergies SE's market cap, and TotalEnergies SE pays the higher dividend (5.22%). Which is the better fit depends on your goals.
| LLY | TTE | |
|---|---|---|
Market Cap | $1.02T | $179.99B |
Sector | Health | Energy |
52-Week High | $1.24K | $93.60 |
52-Week Low | $625.65 | $57.39 |
Enterprise Value | $1.06T | $214.14B |
Dividend Yield | 0.6% | 5.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
TotalEnergies (TTE) trades at $81.23, down 0.2% on the day, with a bullish technical signal supported by moving averages. The company reported a Q1 2026 EPS beat of $2.45 versus $2.22 expected, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Valuation remains attractive with a P/E of 12.08 and P/S of 0.97. Recent news highlights strategic divestments in solar and new LNG shipments to Asia, reflecting a focus on profitable growth areas.
The outlook is positive with a consensus price target of $100, implying 23% upside, supported by 57.6% analyst buy ratings. Risks include ongoing revenue pressure, geopolitical exposure in the Middle East, and regulatory climate mandates. Cash flow stability and shareholder returns via dividends provide a cushion, but execution on production growth and cost management is critical for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
